Group 1 - The core viewpoint of the report is that Guoxin Securities has given Limin Co., Ltd. (002734.SZ) an "outperform" rating due to several positive developments [1] - The company has signed a significant six-year contract worth 1.6 billion yuan with international agricultural giant Bayer [1] - Limin Co., Ltd. is deepening its collaboration with BASF in the field of AI and new pesticide development [1] - The core products of the company are experiencing sustained demand, leading to enhanced profitability [1]

Investment Rating - The investment rating for the company is "Outperform the Market" [5][17]. Core Insights - The company has signed a significant six-year supply contract worth 1.6 billion yuan with Bayer, enhancing its collaboration with major clients [1][9]. - The company is expected to see substantial growth in supply volume to Bayer, with long-term contract prices and profit margins being secured [2][9]. - The company is deepening its cooperation with BASF in the AI and new pesticide development sector, which is anticipated to yield high-barrier new products and growth points [12][17]. - The core products of the company are experiencing favorable market conditions, with price increases contributing positively to profit margins [3][13][15]. Financial Forecast and Performance Metrics - The company forecasts revenue growth from 4.24 billion yuan in 2023 to 5.51 billion yuan in 2027, with a compound annual growth rate of approximately 4.9% [4][21]. - The net profit attributable to shareholders is projected to increase from 620 million yuan in 2023 to 647 million yuan in 2027, reflecting a significant recovery from a low base [4][21]. - Earnings per share (EPS) are expected to rise from 0.17 yuan in 2023 to 1.54 yuan in 2027, indicating strong profitability growth [4][21]. - The company's price-to-earnings (PE) ratio is projected to decrease from 132.9 in 2023 to 14.6 in 2027, suggesting improved valuation as earnings grow [4][21].